• about YM
  • History
  • Business Development
    • In-Licensing
  • Management Team
  • Board of Directors
  • Professional Affiliations

• products
  • CYT387
    • Publications
    • Clinical Trials
  • Nimotuzumab
    • Publications
    • Safety Profile
    • Clinical Trials
    • Consortium
    • Licensee Links
  • CYT997
    • Publications
    • Clinical Trials
  • Clinical Trials
  • Request Medical Info

• investors
  • Financial Reports
  • Regulatory Filings
  • Stock Information
  • Press Releases
  • Calendar of Events
  • Presentations
  • Corporate Governance
  • Analyst Coverage
  • Investor Contacts
  • Email Sign-up

• patients
  • CYT387
  • Nimotuzumab
    • Patients - Canada
    • Patients - USA
    • Patients - Worldwide
  • CYT997

• physicians
  • CYT387
  • Nimotuzumab
  • CYT997

• contact
  • Bus. Dev. Contacts
  • Investor Contacts

Investors

YM BioSciences is a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

The Company is currently advancing three late-stage products:

• CYT387:  JAK 1/2 small molecule inhibitor initially targeting the treatment of a group of hematological disorders known as myeloproliferative neoplasms (MPNs), also known as myeloproliferative disorders.
  
  
• Nimotuzumab:  EGFR-targeting Affinity-Optimized Antibody™ in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation; approved for marketing in 27 countries.
  
  
• CYT997:  novel anti-cancer Vascular Disrupting Agent (VDA) in Phase II clinical development for the treatment of a variety of tumors.
  
  

YM BioSciences is listed on the Toronto Stock Exchange and NYSE Amex Stock Exchange.